Patent Issued for Conjoint therapies for immunomodulation (USPTO 12064418).

A patent has been issued to Curis Inc. for conjoint therapies for immunomodulation. The patent describes methods of modulating the immune response in a subject by using inhibitors of the VISTA pathway and the TIM-3 pathway. These pathways are immune checkpoints that suppress T-cell activation and limit T-cell function and survival. The invention aims to provide more effective and durable therapies for cancer patients who become unresponsive to therapies targeting PD-1, PD-L1, or PD-L2. The patent includes specific compounds and methods for treating various types of cancer, including small cell lung cancer, multiple myeloma, bladder carcinoma, ovarian carcinoma, and pancreatic cancer. [Extracted from the article]